# J&J Completes $14.6 Billion Acquisition of Intra-Cellular Therapies, Adding Caplyta and Neuro Pipeline

> ma · REPORTED · 2025-04-01

Johnson and Johnson completed its $14.6 billion acquisition of Intra-Cellular Therapies, the largest biotech deal of 2025, gaining full control of the approved antipsychotic Caplyta (lumateperone) for schizophrenia and bipolar depression as well as a mid-stage neuro pipeline targeting generalized anxiety disorder and Alzheimer's disease psychosis. The deal closed in April 2025 and complements J&J's existing neuroscience portfolio including Spravato.

About Johnson and Johnson: Intra-Cellular Therapies was a commercial-stage biopharmaceutical company focused on neuropsychiatric disorders, with its flagship product Caplyta (lumateperone) approved for schizophrenia, bipolar depression, and adjunctive major depressive disorder.

- Company: Johnson and Johnson
- Sector: mental health
- Primary source: https://www.biospace.com/press-releases/harmony-biosciences-reports-strong-q2-2025-financial-results-and-reaffirms-2025-revenue-guidance-on-track-to-announce-fragile-x-topline-data-from-phase-3-registrational-trial-in-q3-2025

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.